Flex Pharma (NASDAQ: FLKS) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Flex Pharma to similar companies based on the strength of its analyst recommendations, profitability, valuation, risk, earnings, dividends and institutional ownership.

Valuation & Earnings

This table compares Flex Pharma and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Flex Pharma $1.01 million -$39.49 million -1.84
Flex Pharma Competitors $284.28 million $34.29 million 74.13

Flex Pharma’s competitors have higher revenue and earnings than Flex Pharma. Flex Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Flex Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Flex Pharma -2,655.19% -71.39% -65.49%
Flex Pharma Competitors -5,312.21% -433.82% -39.43%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Flex Pharma and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flex Pharma 0 1 3 0 2.75
Flex Pharma Competitors 857 3201 11603 231 2.71

Flex Pharma currently has a consensus target price of $11.00, indicating a potential upside of 195.70%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.83%. Given Flex Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Flex Pharma is more favorable than its competitors.

Institutional and Insider Ownership

27.3% of Flex Pharma shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 45.4% of Flex Pharma shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Flex Pharma beats its competitors on 6 of the 11 factors compared.

Flex Pharma Company Profile

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.